Transactions in Connection with Share Buy-back Program
06 mai 2024 10h01 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
Genmab Announces Financial Results for the First Quarter of 2024
02 mai 2024 11h01 HE
|
Genmab A/S
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
29 avr. 2024 18h40 HE
|
Genmab A/S
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient...
Transactions in Connection with Share Buy-back Program Genmab
29 avr. 2024 04h24 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Transactions in Connection with Share Buy-back Program Genmab
22 avr. 2024 03h30 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
16 avr. 2024 06h24 HE
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
Transactions in Connection with Share Buy-back Program Genmab
15 avr. 2024 04h07 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Transactions in Connection with Share Buy-back Program
08 avr. 2024 05h44 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
03 avr. 2024 01h34 HE
|
Genmab A/S
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart...
Transactions in Connection with Share Buy-back Program
02 avr. 2024 03h24 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; April 2, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...